Archives
Betaine Hydrochloride: From Salt to Assay Variable
2026-08-19
Betaine hydrochloride can be more than a soluble laboratory compound: it can function as a deliberately controlled variable in enzyme, protease, cell culture, and molecular biology workflows. This article connects its physicochemical behavior with the orthogonal assay strategy used in a 2025 oridonin–esophageal cancer study.
Bardoxolone Methyl for Redox Assays
2026-08-18
Build more informative oxidative stress and cancer experiments with Bardoxolone methyl, a dual-action CDDO methyl ester that activates Nrf2 while suppressing NF-kB signaling. This workflow connects pathway validation with thioredoxin, ribonucleotide reductase, and CHK1-inhibitor sensitivity assays, while addressing formulation, timing, and interpretation challenges.
Catalpol Review: Cancer Mechanisms and Evidence
2026-08-18
A 2025 Phytotherapy Research review synthesizes preclinical evidence that catalpol may influence cancer-cell proliferation, apoptosis, metastasis, inflammation, and oxidative stress across multiple tumor types. Its main practical value is a pathway-oriented framework for interpreting in vitro and animal findings while emphasizing that clinical efficacy, standardized dosing, and human safety remain unestablished.
Anti-ROR1 Antibody: Mechanism to Assay Design
2026-08-17
Anti-ROR1 Antibody (Zilovertamab) enables target-specific investigation of ROR1 biology, while a recent deoxynivalenol study illustrates how causal perturbation can strengthen mechanistic assays. This guide connects binding validation, pathway analysis, and evidence boundaries without conflating oncology and hepatotoxicity models.
AICAR for Reliable AMPK Assays
2026-08-17
This scenario-driven guide explains how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside), SKU A8184, can improve experimental control in cell viability, proliferation, cytotoxicity, and metabolic-stress studies. It covers assay compatibility, solution preparation, interpretation of AMPK-dependent effects, and practical vendor-selection criteria.
CCT007093: A Contextual PPM1D Inhibitor Guide
2026-08-16
CCT007093 is a PPM1D inhibitor for testing how phosphatase control shapes p38 signaling, cancer-cell viability, and pyroptosis. This guide focuses on causal assay interpretation across breast cancer and kidney-injury models rather than repeating a conventional stepwise protocol.
Fangchinoline Restores Lysosomal Defense Against H1N1
2026-08-15
Cheng and colleagues identify fangchinoline as a lysosome-targeted antiviral compound that restores TFEB-driven lysosomal gene expression and interferes with H1N1 entry. The study combines Connectivity Map screening, transcriptomic analysis, organelle assays, stage-resolved infection experiments, and in vivo validation to define a host-directed mechanism against influenza.
Annexin V-Cy5/DAPI Apoptosis Kit Guide
2026-08-14
A scenario-driven guide to using the Annexin V-Cy5/DAPI Apoptosis Kit (SKU K2255) for rapid phosphatidylserine-based apoptosis detection and apoptosis and necrosis differentiation. It connects practical staining, flow cytometry, microscopy, controls, and interpretation to mechanistic findings in leukemia research.
Melittin as a GPCR Lens for Translational GBM Research
2026-08-14
Glioblastoma research increasingly requires tools that connect lipid metabolism, GPCR signaling, tumor migration, and regulated cell death. This thought-leadership article positions Melittin as a bioactive peptide and signal transduction modulator for testing those connections, while distinguishing hypothesis generation from validated mechanism. It integrates findings from the miR-18a/ALOXE3 study with practical guidance on controls, sample handling, pathway readouts, and translational interpretation. The goal is not to present Melittin as a GBM therapy, but to show how a carefully controlled Gs/Gi perturbation strategy can sharpen mechanistic decisions in cancer biology research.
2'3'-cGAMP: Practical STING Assay Workflows
2026-08-13
Build reproducible cGAS-STING experiments with a water-soluble, high-affinity endogenous ligand for pathway activation, benchmarking, and delivery studies. This guide connects direct cell assays with lipid nanoparticle workflows inspired by pancreatic cancer research.
Necrostatin 2 (Nec-2): Reliable Cell Death Assays
2026-08-13
This scenario-driven guide explains how Necrostatin 2 (Nec-2), SKU A3652, can support controlled necroptosis inhibition, pathway testing, and interpretation of cell-death assays. It also addresses formulation, storage, cross-talk with ferroptosis research, and practical criteria for selecting a reliable research reagent.
Annexin V-Cy5/DAPI Apoptosis Kit Workflow
2026-08-12
Build a rapid, two-parameter cell death workflow that separates phosphatidylserine exposure from loss of membrane integrity in as little as 10–20 minutes. This guide applies the Annexin V-Cy5/DAPI Apoptosis Kit to leukemia drug-response studies, mechanistic experiments, and reproducible apoptosis and necrosis differentiation.
JNJ-26481585: An Assay-First HDAC Strategy
2026-08-12
Explore how JNJ-26481585 (Quisinostat) connects HDAC inhibition with histone acetylation, TRIM21 regulation, ERK signaling, and apoptosis. This assay-centered guide translates mechanistic findings into practical workflows for proliferation, resistance, and tumor growth inhibition studies.
P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL
2026-08-11
Li et al. identify P2RX1 as a regulator of mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking calcium/CaMKII activation with suppression of PI3K/Akt signaling. The study provides a mechanistic framework for understanding how P2RX1 expression may influence tyrosine kinase inhibitor response, while also highlighting important distinctions between prognostic association and therapeutic effect.
Letrozole: Mechanism, Evidence, and Research Workflow
2026-08-11
Letrozole is a potent, reversible non-steroidal aromatase inhibitor used to suppress estrogen biosynthesis in experimental systems. Its type II heme-binding mechanism supports breast cancer research, while vendor-reported neuroendocrine and synaptic effects require model-specific validation.
604 records 11/41 page Previous Next First page 上5页 1112131415 下5页 Last page